Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
-1.72%
)
Bitcoin
70,390.44
(
-0.18%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 199615

Friday, 02/12/2016 9:06:35 AM

Friday, February 12, 2016 9:06:35 AM

Post# of 257268
NVS buys PFE’s EU rights to Remicade FoB for undisclosed price:

http://www.sandoz.com/media_center/press_releases_news/global_news/2016-02-12_sandoz-strengthens-biosimilars-portfolio-acquisition-infliximab-in-eea.shtml

Developed by Celltrion, this is the same product that just won the endorsement of an FDA advisory committee (#msg-120426130). PFE’s divestiture of the EU rights to this compound was an EU condition for approving the PFE-HSP merger.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today